gefitinib has been researched along with thiazolyl blue in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (thiazolyl blue) | Trials (thiazolyl blue) | Recent Studies (post-2010) (thiazolyl blue) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,625 | 20 | 1,230 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H | 1 |
| Fujiwara, M; Ishikawa, H; Nakayama, M; Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Takemura, M; Tsurutani, J; Yabuuchi, H; Yasunaga, M | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
4 other study(ies) available for gefitinib and thiazolyl blue
| Article | Year |
|---|---|
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Hypoxia; Mammary Neoplasms, Animal; Mice; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2004 |
Cell growth after withdrawal of gefitinib ("Iressa", ZD1839) in human lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lung Neoplasms; Models, Statistical; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Tetrazolium Salts; Thiazoles | 2005 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |